Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 845-848    DOI: 10.31083/j.ejgo.2020.05.c5526
Case Report Previous articles |
Breast Cancer Metastatic to Vulva - a Case Report
Katselashvili Lika1, *(), Jokhadze Natia1, Katcharava Margarita1, Vardiashvili Nino2
1Department of Hematology and Oncology, Research Institute of Clinical Medicine, Tbilisi, Georgia
2Oncology Department, Innova Medical Center, Tbilisi, Georgia
Download:  PDF(5066KB)  ( 146 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Vulvar cancer is a rare malignancy which accounts 3-5% of all gynecologic tumors. Metastases to the vulva are also rare but can have significant implications for both treatment and prognosis. Here we report a case of vulvar lesion which was the presenting sign of de novo stage IV breast cancer. We describe diagnostic and treatment approach which combined aggressive first-line treatment plus definitive therapy to her vulvar metastasis.
Key words:  Breast cancer      Metastases in the vulva      Invasive ductal carcinoma     
Submitted:  20 February 2020      Accepted:  27 April 2020      Published:  15 October 2020     
*Corresponding Author(s):  KATSELASHVILI LIKA     E-mail:  likakatselashvili@yahoo.com

Cite this article: 

Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.c5526     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/845

[1] Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.
[2] Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.
[3] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[4] Isao Otsuka. Clear cell carcinoma of the vagina followed by breast cancer in a patient without prenatal diethylstilbestrol exposure[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 638-639.
[5] Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now![J]. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.
[6] Sung-Im Do, Hee-Chul Shin, Hee Sung Kim. Clinical significance of MET receptor protein and mRNA expression in invasive breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 240-245.
[7] D. Korfias, J. Contis, M. Frangou-Plemenou, K. Gennatas, A. Kondis, D. Vlachodimitropoulos. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 36-41.
[8] A. Conversano, C. Balleyguier, M.K. De Fremicourt, H. Alkhashnam, C. Mazouni, J. Arfi-Rouche, N. Leymarie, F. Rimareix. Magnetic seed localisation for non-palpable lesions in patients undergoing breast conservative surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 48-53.
[9] S.Wang, W.J. Chen, Z.M. Song, Q. Li, X. Shen, Y.D. Wu, L. Zhu, Q.X. Ma, D.M. Xing. Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 106-109.
[10] M. Englert-Golon, B. Burchardt, R. Słopień, N. Smolarek, S. Sajdak. Ovarian and endometrial cancer after breast cancer - three primary malignancies in a single patient[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 153-154.
[11] T. Aizawa, T. Maebayashi, N. Ishibashi, M. Sakaguchi. Bilateral organizing pneumonia after radiotherapy for bilateral synchronous breast cancers: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1051-1054.
[12] M. El Homsi, A. Barakat, R. Rammal, M. Haidar. Uterine metastasis from invasive ductal breast carcinoma mimicking fibroid features on MRI and detected by FDG PET/CT: role of SUVmax[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1079-1082.
[13] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
[14] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781-786.
[15] S. Bertozzi, A. P. Londero, S. Bernardi, C. Cedolini. Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 787-790.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .